Where does Mainstay Medical Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Mainstay Medical Limited ranks #9,075 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Mainstay Medical Limited hold?

Mainstay Medical Limited holds 35 US utility patents granted between 2015 and 2025, spanning 2 technology areas.

What is Mainstay Medical Limited's Innovation Score?

Mainstay Medical Limited has an Innovation Score of 41.7 out of 100 (top 32% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Mainstay Medical Limited focus on?

Mainstay Medical Limited's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 35 patents, ranking #112 of 1,943 assignees active in that subclass. Grants appear in 2 CPC subclasses total.

Is Mainstay Medical Limited's patent grant rate increasing or decreasing?

Mainstay Medical Limited's recent grant velocity is +27% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Mainstay Medical Limited's patents?

Mainstay Medical Limited's patents average 23.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Mainstay Medical Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Mainstay Medical Limited

USPTO PatentsView assignee record - 35 granted patents across 2 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Mainstay ranks #9,075 of 49,997 tracked US assignees by granted-patent volume, with 35 patents across 2 technology areas.

#9,075
of 49,997 US assignees by volume: Top 32%
by Innovation Score (41.7/100): 23.3
avg claims per patent: +27%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R9075 · Foreign Corporation #9,075 · 35 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 35 grants
UPPER-Q #9,075/49,997
PHOTO-FINISH Mavenir Systems
CPC-NARROW A61N · 2 areas
INNOV-PAR 41.7/100
CLAIMS-DENSE 23.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +27% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Mavenir Systems, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Mainstay’s 41.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.4 pts (30%) Velocity 10.4 pts (25%) Breadth 5.0 pts (12%) Claim depth 14.0 pts (33%)

Qualcomm Incorporated · highest

85
First Principles · near

42
Simple Living… · near

42
GlaxoSmithKline… · near

42
Mainstay Medical · this assignee

42
Response · near

42
3D Lighting… · lowest

7

What this shows Mainstay's Innovation Score is 41.7/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Mainstay?

Each dot is one of Mainstay’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Mainstay’s own 23.3 claims/patent is ABOVE the 15.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Mainstay vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Mainstay's grants concentrate

Mainstay Medical Limited is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2024 (6 grants) versus a trough of 2 in 2016. By volume, Mainstay sits between Mitsubishi Heavy Industries Automotive Thermal Systems, Ltd. and Movano Inc..

Mainstay's three-year grant acceleration

Mainstay Medical Limited shows 14 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Mitsubishi Heavy…

35
Mitsubishi Steel…

35
MRA Systems

35
MSI Computer (She…

35
Mavenir Systems

35
Meditrina

35
Meta View

35
Movano

35
Mainstay Medical ◀

35

What this shows Mainstay holds 35 patents at rank #9,080, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Mainstay

By rank, the assignees closest to #9,080 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Mainstay's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Mainstay, neither rank-band nor same-CPC leaders (those blocks stay above). In A61N (Electrotherapy), Mainstay ranks #112 of 1,943 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (42 here).

GlaxoSmithKline Intellectual Property (No. 4) Limited 42 Response Technologies, LLC 42 First Principles, Inc. 42 Simple Living Solutions, LLC 42

Mainstay's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Mainstay Medical Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	11.4%
2016	2	5.7%
2018	5	14.3%
2019	4	11.4%
2020	2	5.7%
2021	3	8.6%
2022	4	11.4%
2023	4	11.4%
2024	6	17.1%
2025partial year	1	2.9%

Which technologies does Mainstay Medical Limited patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 35

A61B - DIAGNOSIS; SURGERY; Identification 16

Top 2 of 2 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Mainstay Medical Limited's patent record in context - here's where to go next.

Mainstay Medical Limited's lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #9,075 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Mainstay Medical Limited against Mitsubishi Heavy Industries Automotive Thermal Systems, Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.